The science behind 2Strands — a proprietary rare variant enrichment technology that makes ultra-deep MRD monitoring accurate, affordable and scalable.
Early cancer recurrence detection remains challenging, as imaging often identifies relapse too late, while existing ctDNA tests are either costly or lack sufficient sensitivity to detect the earliest signs of recurrence.
Our proprietary rare variant enrichment technology selectively concentrates mutant alleles prior to sequencing — decoupling sensitivity from sequencing depth.
2Strands Recura is an innovative blood test for accurate and affordable Minimal Residual Disease (MRD) monitoring.
Powered by 2Strands Biosciences' proprietary allele enrichment technology, 2Strands Recura selectively enriches target mutations while depleting non-target alleles.
This reduces sequencing requirements, enables detection of multiple low-frequency mutations, and helps balance cost, sensitivity, and specificity to better guide treatment decisions and improve patient outcomes.
Whether you're a clinician, researcher or partner — get in touch to explore a collaboration.